Vanderbilt University Medical Center has a new weapon in the fight against COVID-19 — an investigational antibody treatment approved last month for emergency use in COVID-19 outpatients at high risk of developing severe disease or requiring hospital care.

Vanderbilt University Medical Center investigators have identified a key molecular player in the early events of the inflammatory response to infection. The findings suggest new therapeutic possibilities for enhancing the inflammatory response to protect against pathogens and for blocking inflammation gone awry in diseases like arthritis and atherosclerosis.

COVID-19 spreads faster and more widely throughout U.S. households than previously reported, according to new preliminary research from a multicenter study led by Vanderbilt University Medical Center researchers and published in, a weekly report from the Centers for Disease Control and Prevention (CDC).

Studies using large DNA biobanks revealed genetic variants associated with penicillin allergy, the most common type of drug-induced allergic reaction.

Vanderbilt University Medical Center investigators are leading a new study that examines the transmission of SARS-CoV-2, the virus that causes COVID-19, within households in Nashville.

American Airlines has created a new Travel Health Advisory Panel that includes Vanderbilt University Medical Center infectious disease experts to advise on health and cleaning matters as travelers return over the summer.

Vanderbilt Institute for Global Health (VIGH) has received a new research training grant and a renewal for an existing training program from the Fogarty International Center (FIC) of the National Institutes of Health (NIH) to build HIV-focused research capacity with key partners in Nigeria and Mozambique.